Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherDRUG METABOLISM AND DISPOSITION

Selective Deficiency of Debrisoquine 4-Hydroxylase Activity in Mouse Liver Microsomes

Yasuhiro Masubuchi, Takashi Iwasa, Shin Hosokawa, Tokuji Suzuki, Toshiharu Horie, Susumu Imaoka, Yoshihiko Funae and Shizuo Narimatsu
Journal of Pharmacology and Experimental Therapeutics September 1997, 282 (3) 1435-1441;
Yasuhiro Masubuchi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takashi Iwasa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shin Hosokawa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tokuji Suzuki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toshiharu Horie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susumu Imaoka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshihiko Funae
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shizuo Narimatsu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Cytochrome P450 enzymes belonging to the CYP2D subfamily have been shown to be one of determinants of the polymorphic drug oxidations in the human and the rat. Debrisoquine 4-hydroxylation is a typical reaction catalyzed by these enzymes. However, various strains of mice were observed to have much lower debrisoquine 4-hydroxylase activity than Wistar rats, whereas other monooxygenase activities in mice toward bunitrolol, propranolol, imipramine and amitriptyline, which are mediated by the CYP2D enzymes in the rat, were comparable to those of the rats. Immunoblot analysis of mouse liver microsomes with an antibody raised against a rat CYP2D enzyme indicated that the mouse liver contained a P450 enzyme(s) immunochemically related to the rat CYP2D enzyme. The antibody inhibited propranolol ring-hydroxylase and imipramine 2-hydroxylase activities, as well as testosterone 16α-hydroxylase activity, a typical reaction of mouse CYP2D9, but not debrisoquine 4-hydroxylase activity in mouse liver microsomes. We partially purified a P450 enzyme (designated P450 ML2d) from livers of male ddY mice by monitoring the cross-reactivity with the antibody. The partially purified enzyme was indicated to belong to the CYP2D subfamily from its N-terminal amino acid sequence, but the homology of the sequence to other CYP2D enzymes of the mouse (CYP2D9–11) was 62%, suggesting that P450 ML2d is a novel P450 enzyme. P450 ML2d had the oxidation activities for the rat CYP2D-substrates, such as propranolol 4-hydroxylation and imipramine 2-hydroxylation, in higher rates than those of the microsomes, but did not exhibit debrisoquine 4-hydroxylase activity. Our result is the first finding that a mouse CYP2D enzyme also metabolizes substrates for the rat CYP2D enzyme, in addition to steroids, but the enzyme had a limited specificity for the substrates of the CYP2D enzymes of the rat and the human.

Footnotes

  • Send reprint requests to: Dr. Shizuo Narimatsu, Associate Professor, Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Chiba University, 1–33 Yayoi-cho, Inage-ku, Chiba 263, Japan.

  • Abbreviations:
    P450 or CYP
    cytochrome P450
    DA
    Dark Agouti
    G-6-P
    glucose 6-phosphate
    G-6-PDH
    glucose 6-phosphate dehydrogenase
    SDS-PAGE
    sodium dodecyl sulfate-polyacrylamide gel electrophoresis
    • Received December 9, 1996.
    • Accepted May 21, 1997.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 282, Issue 3
1 Sep 1997
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Selective Deficiency of Debrisoquine 4-Hydroxylase Activity in Mouse Liver Microsomes
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherDRUG METABOLISM AND DISPOSITION

Selective Deficiency of Debrisoquine 4-Hydroxylase Activity in Mouse Liver Microsomes

Yasuhiro Masubuchi, Takashi Iwasa, Shin Hosokawa, Tokuji Suzuki, Toshiharu Horie, Susumu Imaoka, Yoshihiko Funae and Shizuo Narimatsu
Journal of Pharmacology and Experimental Therapeutics September 1, 1997, 282 (3) 1435-1441;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
OtherDRUG METABOLISM AND DISPOSITION

Selective Deficiency of Debrisoquine 4-Hydroxylase Activity in Mouse Liver Microsomes

Yasuhiro Masubuchi, Takashi Iwasa, Shin Hosokawa, Tokuji Suzuki, Toshiharu Horie, Susumu Imaoka, Yoshihiko Funae and Shizuo Narimatsu
Journal of Pharmacology and Experimental Therapeutics September 1, 1997, 282 (3) 1435-1441;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • A New Interpretation of Salicylic Acid Transport across the Lipid Bilayer: Implications of pH-Dependent but not Carrier-Mediated Absorption from the Gastrointestinal Tract
  • Characterization of Efflux Transport of Organic Anions in a Mouse Brain Capillary Endothelial Cell Line
  • Activation of Human Liver 3α-Hydroxysteroid Dehydrogenase by Clofibrate Derivatives
Show more DRUG METABOLISM AND DISPOSITION

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics